Drug Profile


Alternative Names: Aciphex; AcipHex Sprinkle; E-3810 - Eisai; LY-307640; Pariet; Pariprazole; Rabecure Pack 400; Rabecure Pack 800; Rabefine; Rabeloc; Rabeprazole sodium

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eisai Co Ltd
  • Developer EA Pharma; Eisai Co Ltd
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiulcers; Gastric antisecretories; Small molecules
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Duodenal ulcer; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; Peptic ulcer; Reflux oesophagitis; Zollinger-Ellison syndrome
  • Discontinued Dyspepsia

Most Recent Events

  • 22 Sep 2017 Japanese regulatory body approves use of rabeprazole in Reflux oesophagitis (Maintenance therapy) in Japan (PO, Tablet)
  • 22 Sep 2017 Adverse events and efficacy data from a phase III trial in Reflux oesophagitis released by Eisai
  • 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top